ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
139,400
-33,300 (-19.28%)
Apr 28, 2026, 3:30 PM KST
102.03%
Market Cap 7.80T
Revenue (ttm) 79.35B
Net Income (ttm) -37.81B
Shares Out 55.99M
EPS (ttm) -734.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,924,760
Average Volume 568,463
Open 144,900
Previous Close 172,700
Day's Range 131,900 - 145,200
52-Week Range 57,700 - 257,500
Beta 0.60
RSI 37.60
Earnings Date May 13, 2026

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatm... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2016
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2025, ABL Bio's revenue was 79.35 billion, an increase of 137.55% compared to the previous year's 33.40 billion. Losses were -37.81 billion, -31.92% less than in 2024.

Financial Statements

News

There is no news available yet.